Monte Rosa Therapeutics (GLUE) Earnings Date, Estimates & Call Transcripts $7.67 -0.01 (-0.13%) (As of 12/17/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Monte Rosa Therapeutics Latest Earnings SummaryActual EPS (Nov. 7) -$0.29 Beat By $0.16 Consensus EPS (Nov. 7) -$0.45 Monte Rosa Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.29, which topped analysts' consensus estimates of -$0.45 by $0.16. Quarterly revenue was reported to be $9.22 million, above the consensus estimate of $4.54 million. With a trailing EPS of -$1.83, Monte Rosa Therapeutics' earnings are expected to grow next year, from ($1.49) to ($1.41) per share. Get Monte Rosa Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataGLUE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GLUE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Monte Rosa Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.60-$0.60-$0.60Q2 20241-$0.37-$0.37-$0.37Q3 20241-$0.34-$0.34-$0.34Q4 20241-$0.20-$0.20-$0.20FY 20244-$1.51-$1.51-$1.51Q1 20251-$0.21-$0.21-$0.21Q2 20251-$0.22-$0.22-$0.22Q3 20251-$0.24-$0.24-$0.24Q4 20251-$0.25-$0.25-$0.25FY 20254($0.92)($0.92)($0.92) Monte Rosa Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/7/2024Q3 2024-$0.45-$0.29+$0.16-$0.29$4.54M$9.22M8/8/2024--$0.50-$0.43+$0.07-$0.43$3.20M$4.70M5/9/2024Q1 2024-$0.56-$0.53+$0.03-$0.53$4.29M$1.06M3/14/2024Q4 2023-$0.57-$0.58 -$0.01-$0.58--11/9/2023Q3 2023-$0.75-$0.70+$0.05-$0.70--8/10/2023Q2 2023-$0.72-$0.71+$0.01-$0.71-- Get the Latest News and Ratings for GLUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-$0.70-$0.65+$0.05-$0.65--3/16/2023Q4 2022-$0.64-$0.63+$0.01-$0.63-- Monte Rosa Therapeutics Earnings - Frequently Asked Questions When did Monte Rosa Therapeutics announce their last quarterly earnings? Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on GLUE's earnings history. Did Monte Rosa Therapeutics beat their earnings estimates last quarter? In the previous quarter, Monte Rosa Therapeutics (NASDAQ:GLUE) reported ($0.29) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.45) by $0.16. Learn more on analysts' earnings estimate vs. GLUE's actual earnings. How much revenue does Monte Rosa Therapeutics generate each year? Monte Rosa Therapeutics (NASDAQ:GLUE) has a recorded annual revenue of $14.98 million. How much profit does Monte Rosa Therapeutics generate each year? Monte Rosa Therapeutics (NASDAQ:GLUE) has a recorded net income of -$135.35 million. GLUE has generated -$1.83 earnings per share over the last four quarters. What is Monte Rosa Therapeutics's EPS forecast for next year? Monte Rosa Therapeutics's earnings are expected to grow from ($1.49) per share to ($1.41) per share in the next year. More Earnings Resources from MarketBeat Related Companies HRMY Earnings Results GLPG Earnings Results XNCR Earnings Results ARQT Earnings Results RCUS Earnings Results NRIX Earnings Results IMCR Earnings Results KNSA Earnings Results OCUL Earnings Results TVTX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.Click here and I’ll show you exactly how to position your money This page (NASDAQ:GLUE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
